KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Convertible Debt (2021 - 2025)

Pacific Biosciences Of California (PACB) has 5 years of Convertible Debt data on record, last reported at $645.4 million in Q4 2025.

  • For Q4 2025, Convertible Debt changed 0.33% year-over-year to $645.4 million; the TTM value through Dec 2025 reached $645.4 million, changed 0.33%, while the annual FY2025 figure was $645.4 million, 0.33% changed from the prior year.
  • Convertible Debt reached $645.4 million in Q4 2025 per PACB's latest filing, roughly flat from $645.2 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $896.8 million in Q1 2023 and bottomed at $645.2 million in Q3 2025.
  • Average Convertible Debt over 5 years is $832.6 million, with a median of $893.0 million recorded in 2024.
  • Peak YoY movement for Convertible Debt: rose 0.13% in 2024, then dropped 27.77% in 2025.
  • A 5-year view of Convertible Debt shows it stood at $896.1 million in 2021, then grew by 0.07% to $896.7 million in 2022, then fell by 0.5% to $892.2 million in 2023, then fell by 27.43% to $647.5 million in 2024, then dropped by 0.33% to $645.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $645.4 million in Q4 2025, $645.2 million in Q3 2025, and $646.4 million in Q2 2025.